Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28867441 | 1.00 | HPGD (0.54) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL16827771 | 1.00 | HPGD (0.54) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL2285980 | 0.92 | HPGD (0.51) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL2285975 | 0.92 | HPGD (0.51) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL2995910 | 0.85 | NR1H2 (0.43) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL2995906 | 0.85 | NR1H2 (0.43) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL30364451 | 0.84 | MEN1 (0.54) | HPGDRECQLKMT2AEPHX1ABL1 | |
| SCHEMBL19194947 | 0.84 | MEN1 (0.54) | HPGDRECQLKMT2AEPHX1ABL1 | |
| SCHEMBL21348930 | 0.84 | MEN1 (0.54) | HPGDRECQLKMT2AEPHX1ABL1 | |
| SCHEMBL7603656 | 0.84 | HPGD (0.57) | HPGDRECQLPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425510-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.P.A. (IT) | 2024-12-26 | — | — | US | claimed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-119564686-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119523983-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119424429-A | DGK alpha inhibitors as immune activation substituted aminoquinolones of (2) | 拜耳公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240425510-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | OLON S.P.A. (IT) | 2024-12-26 | — | — | US | disclosed |
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-115611902-B | Protein degradation compound designed based on Bruton tyrosine kinase ligand and application thereof | 标新生物医药科技(上海)有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3083591-B1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2018-01-03 | — | — | EP | disclosed |
| US-9751861-B2 | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9751861-B2 | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9751861-B2 | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-20160311798-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160311798-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20160311798-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2016-10-27 | — | — | US | disclosed |
| EP-3083591-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | Merck Patent GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015090496-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015090496-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311798-A1 | N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | PDK1, PDK3, PDK2 | HPGD 140/4885RECQL 784/4885PTPN2 3977/4885 |
| US-20240425510-A1 | PROCESS FOR THE PREPARATION OF ZANUBRUTINIB | BCL6B, BCL6, BCL9 | HPGD 3528/4885RECQL 4491/4885PTPN2 1679/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | HPGD 1407/4885RECQL 8/4885PTPN2 2357/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | HPGD 3078/4885RECQL 4409/4885PTPN2 65/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | HPGD 4116/4885RECQL 66/4885PTPN2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.